Literature DB >> 16186542

Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.

J C H van Oostrom1, R P Maguire, C C Verschuuren-Bemelmans, L Veenma-van der Duin, J Pruim, R A C Roos, K L Leenders.   

Abstract

Among 27 preclinical carriers of the Huntington disease mutation (PMC), the authors found normal striatal values for MRI volumetry in 88% and for fluorodesoxyglucose PET metabolic index in 67%. Raclopride PET binding potential (RAC-BP) was decreased in 50% and correlated with increases in the product of age and CAG repeat length (p < 0.0005). Dopamine D2 receptor availability measured by RAC-BP seems the most sensitive indicator of early neuronal impairment in PMC.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16186542     DOI： 10.1212/01.wnl.0000176071.08694.cc

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  24 in total

Review 1.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.

Authors:  Shafik N Wassef; John Wemmie; Casey P Johnson; Hans Johnson; Jane S Paulsen; Jeffrey D Long; Vincent A Magnotta
Journal:  Mov Disord       Date:  2015-03-29       Impact factor: 10.338

3.  Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.

Authors:  Andreas Matusch; Carsten Saft; David Elmenhorst; Peter H Kraus; Ralf Gold; Hans-Peter Hartung; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

4.  Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.

Authors:  Meike Herben-Dekker; Joost C H van Oostrom; Raymund A C Roos; Caroline K Jurgens; Marie-Noëlle W Witjes-Ané; Hubertus P H Kremer; Klaus L Leenders; Jacoba M Spikman
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

Review 5.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

6.  Benign hereditary chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation.

Authors:  Takashi Konishi; Satoshi Kono; Masaya Fujimoto; Tatsuhiro Terada; Kozo Matsushita; Yasuomi Ouchi; Hiroaki Miyajima
Journal:  J Neurol       Date:  2012-07-24       Impact factor: 4.849

7.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

8.  Thalamic metabolism and symptom onset in preclinical Huntington's disease.

Authors:  A Feigin; C Tang; Y Ma; P Mattis; D Zgaljardic; M Guttman; J S Paulsen; V Dhawan; D Eidelberg
Journal:  Brain       Date:  2007-09-24       Impact factor: 13.501

9.  Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease.

Authors:  Wim Vandenberghe; Philippe Demaerel; René Dom; Frederik Maes
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

10.  Four decades of neurodegenerative disease research: how far we have come!

Authors:  Anne B Young
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.